FreeTheAI

BioInvent Details BI-1808 Trial Data and Plans Phase C Triplet Study in 2027

NeutralLow impact
BINVSEK 23.40 −0.43%

BioInvent International AB (OMXSTO:BINV) published an abstract outlining previously communicated Phase 1/2a results for its drug candidate BI-1808 in combination with pembrolizumab. The study evaluated patients with platinum-resistant ovarian cancer, and enrollment for the combination cohort is now complete.

The trial recorded a median progression-free survival of 10.3 months using iRECIST criteria and 4.2 months under RECIST criteria. The difference highlights evaluation nuances in immunotherapeutic cancer response. Preclinical findings also showed synergy when combining BI-1808 with paclitaxel, establishing the rationale for broader clinical evaluation.

BioInvent plans to launch Part C of the study in the first quarter of 2027. This stage will evaluate a randomized triplet regimen combining BI-1808 with paclitaxel, with or without bevacizumab. Initial data from Part C is expected in the second half of 2027, subject to patient enrollment. Shares of BioInvent were down 0.43% at 23.4 SEK.

Key points

  • BioInvent completed enrollment for the Phase 1/2a combination cohort evaluating BI-1808 and pembrolizumab in platinum-resistant ovarian cancer.
  • Trial data showed a median progression-free survival of 10.3 months under iRECIST assessment and 4.2 months under RECIST assessment.
  • The company plans to initiate a randomized triplet study combining BI-1808 with paclitaxel (with or without bevacizumab) in Q1 2027.
  • Initial results from the upcoming triplet study are anticipated in the second half of 2027, depending on enrollment timelines.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the results of BioInvent's BI-1808 combination trial?

In platinum-resistant ovarian cancer, combining BI-1808 with pembrolizumab demonstrated a median progression-free survival of 10.3 months using iRECIST criteria and 4.2 months using RECIST criteria.

What is BioInvent's next clinical step for BI-1808?

BioInvent plans to launch Part C, a randomized triplet trial with paclitaxel with or without bevacizumab, in the first quarter of 2027. Preliminary data is expected in the second half of 2027.